Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...
In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...
3don MSN
Q4 2024 Management View CEO Ameet Mallik highlighted that 2024 was focused on execution, achieving key milestones, advancing ZYNLONTA, and strengthening the balance sheet. The company completed ...
• In advanced-stage HL, reduction of chemotherapy or radiotherapy after a negative interim PET scan is probably beneficial for overall survival. • Treatment escalation with rituximab after a positive ...
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...
Initial data for AlloNK® from autoimmune program expected H1 2025Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL ...
Wojciech Jurczak, MD, PhD, discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...
Henlius has accelerated breakthroughs in its innovation pipeline and efficiently expanded its global footprint, unlocking further growth potential and driving sustainable, high-quality development. Up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback